Search - tctmd.com

Displaying 1 - 20 of 175

Sort: Relevancy | Date

Presentation TCT 2025

TCT 245: Final 7-Year Results from the COMPARE-ABSORB Trial: Randomized Comparison of Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis. Detailed analysis of long lesions

Presenter: Robert-Jan Van Geuns

October 28, 2025

Presentation TCT 2024

TCT 1012: Pre-Emptive PCI in Vulnerable Coronary Plaques Reduces Biomechanical and Anatomic High-Risk Features: The PROSPECT ABSORB Trial

Presenter: Diaa Hakim

October 29, 2024

Presentation TCT 2024

TCT 368: Coronary Physiology After Drug-Eluting Absorbable Metallic Scaffold

Presenter: Ryan Wallace

October 29, 2024

Presentation TCT 2024

TCT 360: Mechanisms of Lumen Reduction After Implantation of a Drug-Eluting Absorbable Metal Scaffold

Presenter: Kirstine Hansen

October 27, 2024

Presentation TCT 2023

TCT 817: ABSORB bioresorbable scaffold (BRS) late restenosis treated with novel Magmaris BRS

Presenter: Jorgo Kostov

October 25, 2023

Presentation TCT 2022

TCT 60: The impact of implantation techniques in Absorb BVS and Xience EES on lesion oriented-outcomes at complete five-year follow-up – an AIDA trial QCA substudy

Presenter: Mick Renkens

September 17, 2022

Presentation TCT 2022

TCT 52: Structural and Functional Evaluation of Coronary Arteries Treated With Absorb Bioresorbable Vascular Scaffold at 5-Year Follow-Up

Presenter: Luis Goncalves-Ramírez

September 17, 2022

Presentation TCT 2020

The PROSPECT ABSORB Trial: Randomized Evaluation of Vulnerable Plaque Treatment with Percutaneous Coronary Intervention

Presenter: Gregg Stone

October 14, 2020

Presentation TCT 2019

The Post-Absorb BVS Era: Lessons Learned and Implications for Trial Design and Device Approval

Presenter: Andrew Farb

September 28, 2019

Presentation TCT 2019

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

Presenter: Renu Virmani

September 28, 2019

Presentation TCT 2019

TCT 7: Blinded Outcomes Assessment of Absorb Bioresorbable Scaffolds Implanted With Improved Technique: Two-year Results From the ABSORB IV Randomized Trial

Presenter: Gregg Stone

September 28, 2019

Presentation TCT 2019

ABSORB 5-Year Pooled Analysis: Improving Very Late Outcomes of the Absorb Bioresorbable Scaffold in Coronary Artery Disease From 4 Randomized Trials

Presenter: Gregg Stone

September 27, 2019

Presentation TCT 2019

Detection of Vulnerable Patients by NIRS (PROSPECT II) and Treatment (PROSPECT ABSORB) Rationale and Update

Presenter: David Erlinge

September 27, 2019

Presentation TCT 2019

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

Presenter: Robert-Jan Van Geuns

September 25, 2019

Presentation TCT 2019

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Presenter: Run-Lin Gao

September 25, 2019

Presentation TCT 2019

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

Presenter: Jens Wiebe

September 25, 2019

Presentation TCT 2018

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

Presenter: Felix Mahfoud, Patrick W. Serruys, Pieter C. Smits

September 25, 2018

Presentation TCT 2018

ABSORB IV: A Blinded Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in an Expanded Patient Population Using Optimized Technique

Presenter: Felix Mahfoud, Patrick W. Serruys, Gregg W. Stone

September 25, 2018

Presentation TCT 2018

Falcon Development and Status

Presenter: Bernard R. Chevalier, Stephen G. Ellis, Richard J. Rapoza

September 22, 2018

Presentation TCT 2018

How to Improve BRS Outcomes: Focus on Imaging and Technique

Presenter: Bernard R. Chevalier, Stephen G. Ellis, Ziad A. Ali

September 22, 2018

Advertisement

TCT 245: Final 7-Year Results from the COMPARE-ABSORB Trial: Randomized Comparison of Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis. Detailed analysis of long lesions

TCT 1012: Pre-Emptive PCI in Vulnerable Coronary Plaques Reduces Biomechanical and Anatomic High-Risk Features: The PROSPECT ABSORB Trial

TCT 368: Coronary Physiology After Drug-Eluting Absorbable Metallic Scaffold

TCT 360: Mechanisms of Lumen Reduction After Implantation of a Drug-Eluting Absorbable Metal Scaffold

TCT 817: ABSORB bioresorbable scaffold (BRS) late restenosis treated with novel Magmaris BRS

TCT 60: The impact of implantation techniques in Absorb BVS and Xience EES on lesion oriented-outcomes at complete five-year follow-up – an AIDA trial QCA substudy

TCT 52: Structural and Functional Evaluation of Coronary Arteries Treated With Absorb Bioresorbable Vascular Scaffold at 5-Year Follow-Up

The PROSPECT ABSORB Trial: Randomized Evaluation of Vulnerable Plaque Treatment with Percutaneous Coronary Intervention

The Post-Absorb BVS Era: Lessons Learned and Implications for Trial Design and Device Approval

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

TCT 7: Blinded Outcomes Assessment of Absorb Bioresorbable Scaffolds Implanted With Improved Technique: Two-year Results From the ABSORB IV Randomized Trial

ABSORB 5-Year Pooled Analysis: Improving Very Late Outcomes of the Absorb Bioresorbable Scaffold in Coronary Artery Disease From 4 Randomized Trials

Detection of Vulnerable Patients by NIRS (PROSPECT II) and Treatment (PROSPECT ABSORB) Rationale and Update

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

ABSORB IV: A Blinded Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in an Expanded Patient Population Using Optimized Technique

Falcon Development and Status

How to Improve BRS Outcomes: Focus on Imaging and Technique

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content